Can intravenous immunoglobulin improve antibody-mediated botulinum toxin therapy failure? (Q73264271)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11104225%20AND%20SRC:MED&resulttype=core&format=json

2 November 2019

title

Can intravenous immunoglobulin improve antibody-mediated botulinum toxin therapy failure? (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11104225%20AND%20SRC:MED&resulttype=core&format=json

2 November 2019

D Dressler

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11104225%20AND%20SRC:MED&resulttype=core&format=json

2 November 2019

U Zettl

series ordinal

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11104225%20AND%20SRC:MED&resulttype=core&format=json

2 November 2019

R Benecke

series ordinal

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11104225%20AND%20SRC:MED&resulttype=core&format=json

2 November 2019

H Bigalke

series ordinal

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11104225%20AND%20SRC:MED&resulttype=core&format=json

2 November 2019

publication date

1 November 2000

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11104225%20AND%20SRC:MED&resulttype=core&format=json

2 November 2019

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11104225%20AND%20SRC:MED&resulttype=core&format=json

2 November 2019

volume

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11104225%20AND%20SRC:MED&resulttype=core&format=json

2 November 2019

issue

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11104225%20AND%20SRC:MED&resulttype=core&format=json

2 November 2019

page(s)

1279-1281

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11104225%20AND%20SRC:MED&resulttype=core&format=json

Long-term treatment of cervical dystonia with botulinum toxin A: efficacy, safety, and antibody frequency. German Dystonia Study Group

2 November 2019

cites work

1 reference

https://api.crossref.org/works/10.1002%2F1531-8257%28200011%2915%3A6%3C1279%3A%3AAID-MDS1040%3E3.0.CO%3B2-4

Depletion of neutralising antibodies resensitises a secondary non-responder to botulinum A neurotoxin

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1531-8257%28200011%2915%3A6%3C1279%3A%3AAID-MDS1040%3E3.0.CO%3B2-4

High-dose intravenous gammaglobulin for idiopathic thrombocytopenic purpura in childhood

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1531-8257%28200011%2915%3A6%3C1279%3A%3AAID-MDS1040%3E3.0.CO%3B2-4

Effects of intravenous immunoglobulin on muscle weakness and calcium-channel autoantibodies in the Lambert-Eaton myasthenic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1531-8257%28200011%2915%3A6%3C1279%3A%3AAID-MDS1040%3E3.0.CO%3B2-4

High-dose intravenous immunoglobulin in the treatment of demyelinating neuropathy associated with monoclonal gammopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1531-8257%28200011%2915%3A6%3C1279%3A%3AAID-MDS1040%3E3.0.CO%3B2-4

Multifocal motor neuropathy: response to human immune globulin

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1531-8257%28200011%2915%3A6%3C1279%3A%3AAID-MDS1040%3E3.0.CO%3B2-4

Intravenous immunoglobulin treatment in patients with motor neuron syndromes associated with anti-GM1 antibodies: a double-blind, placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1531-8257%28200011%2915%3A6%3C1279%3A%3AAID-MDS1040%3E3.0.CO%3B2-4

Treatment of multifocal motor neuropathy with high dose intravenous immunoglobulins: a double blind, placebo controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1531-8257%28200011%2915%3A6%3C1279%3A%3AAID-MDS1040%3E3.0.CO%3B2-4

ANCA anti-idiotype antibodies and the treatment of systemic vasculitis with intravenous immunoglobulin

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1531-8257%28200011%2915%3A6%3C1279%3A%3AAID-MDS1040%3E3.0.CO%3B2-4

Idiotypy and idiotypic networks: a time to redefine concepts

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1531-8257%28200011%2915%3A6%3C1279%3A%3AAID-MDS1040%3E3.0.CO%3B2-4

Selectivity of Recognition of Variable (V) Regions of Autoantibodies by Intravenous Immunoglobulin (IVIg)

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1531-8257%28200011%2915%3A6%3C1279%3A%3AAID-MDS1040%3E3.0.CO%3B2-4

Botulinum A Toxin Therapy: Neutralizing and Nonneutralizing Antibodies—Therapeutic Consequences

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1531-8257%28200011%2915%3A6%3C1279%3A%3AAID-MDS1040%3E3.0.CO%3B2-4

Electromyographic quantification of the paralysing effect of botulinum toxin in the sternocleidomastoid muscle

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1531-8257%28200011%2915%3A6%3C1279%3A%3AAID-MDS1040%3E3.0.CO%3B2-4

The EBD test--a clinical test for the detection of antibodies to botulinum toxin type A

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1531-8257%28200011%2915%3A6%3C1279%3A%3AAID-MDS1040%3E3.0.CO%3B2-4

Tetanus toxin blocks the neuromuscular transmission in vitro like botulinum a toxin

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1531-8257%28200011%2915%3A6%3C1279%3A%3AAID-MDS1040%3E3.0.CO%3B2-4

10.1002/1531-8257(200011)15:6<1279::AID-MDS1040>3.0.CO;2-4

21 January 2018

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11104225%20AND%20SRC:MED&resulttype=core&format=json

2 November 2019

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11104225%20AND%20SRC:MED&resulttype=core&format=json